Trial · NCT03447990
Results by group209
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 60 of 209
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Danicamtiv 550mg | Change in QTcF from Baseline > 60msec | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 2 Danicamtiv 400mg | Change in QTcF from Baseline > 60msec | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 2 Danicamtiv 500mg | Change in QTcF from Baseline > 60msec | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 2 Placebo | Change in QTcF from Baseline > 60msec | 1 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Danicamtiv 175mg | Change in PR from baseline > 25% | 1 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Danicamtiv 350mg | Change in PR from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Placebo | Change in PR from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Danicamtiv 450mg | Change in PR from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Danicamtiv 525mg | Change in PR from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Danicamtiv 550mg | Change in PR from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 2 Danicamtiv 400mg | Change in PR from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 2 Danicamtiv 500mg | Change in PR from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 2 Placebo | Change in PR from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Danicamtiv 175mg | Change in QRS from baseline > 25% | 1 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Danicamtiv 350mg | Change in QRS from baseline > 25% | 1 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Placebo | Change in QRS from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Danicamtiv 450mg | Change in QRS from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Danicamtiv 525mg | Change in QRS from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 1 Danicamtiv 550mg | Change in QRS from baseline > 25% | 0 | Participants | |
| Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts | SAD Cohort 2 Danicamtiv 400mg | Change in QRS from baseline > 25% | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03447990/results?page=3